Lenzetto (Estradiol)

Estradiol in Lenzetto penetrates the skin and enters the bloodstream, where it binds to estrogen receptors ERα and ERβ in target tissues. This receptor activation regulates gene transcription, leading to physiological effects that restore estrogen levels, improve thermoregulation, and support bone remodeling.

The prescribed dose of Lenzetto is determined by the treating physician based on the individual’s clinical condition, severity of symptoms, and response to therapy. The prescriber selects the appropriate patch strength and replacement interval, typically ranging from weekly to bi‑weekly changes.

The safety of Lenzetto in pregnancy and lactation has not been established. Estradiol therapy is generally contraindicated during pregnancy because it may affect fetal development, and it is not recommended while breastfeeding due to potential exposure to the infant.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenzetto delivers estradiol through the skin, bypassing first‑pass hepatic metabolism, which can result in more stable serum levels and potentially lower risk of liver‑related side effects. Oral tablets undergo hepatic conversion, may require higher doses, and can have different interaction profiles.

Store Lenzetto at room temperature, preferably below 25 °C, in its original sealed pouch. Protect the patch from moisture, direct sunlight, and excessive heat. Keep out of reach of children and do not use if the packaging is damaged.

The patch is applied to clean, dry, hair‑free skin on the lower abdomen or buttock. Press firmly for several seconds to ensure adhesion, then replace the patch according to the prescribing interval, usually once a week. Rotate application sites to minimize skin irritation.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, myocardial infarction, severe allergic reactions, and potential stimulation of hormone‑sensitive cancers. Patients should be monitored for signs of blood clots, chest pain, sudden neurological changes, or abnormal uterine bleeding.

Lenzetto is contraindicated in women with known or suspected estrogen‑dependent malignancies (e.g., breast or endometrial cancer), active thromboembolic disease, unexplained vaginal bleeding, severe liver disease, or a history of severe allergic reaction to estradiol or patch components.